The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

September 20, 2013

Cost, Value and Access of Personalized Medicine

Linda Bosserman provides an overview of the nuances of personalized medicine as it relates to cost, value and access

October 28, 2014

Success of Cytoreductive Therapy

Listen as Dr. Mesa presents his opinion on the success of cytoreductive therapy with patients with polycythemia vera.Supported through funding from Incyte